AR121515A1 - Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores - Google Patents

Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores

Info

Publication number
AR121515A1
AR121515A1 ARP210100576A ARP210100576A AR121515A1 AR 121515 A1 AR121515 A1 AR 121515A1 AR P210100576 A ARP210100576 A AR P210100576A AR P210100576 A ARP210100576 A AR P210100576A AR 121515 A1 AR121515 A1 AR 121515A1
Authority
AR
Argentina
Prior art keywords
efficacy
methods
evaluate
compositions
transporter inhibitors
Prior art date
Application number
ARP210100576A
Other languages
English (en)
Inventor
Hong Sun
Xiaojun Li
Zafrin Dhali
Haiping Lu
Wilson Wu
Wen Luo
John W Whitaker
Original Assignee
Denovo Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma Llc filed Critical Denovo Biopharma Llc
Publication of AR121515A1 publication Critical patent/AR121515A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere al campo de la farmacogenómica, el cual aplica uno o más biomarcadores genómicos y los dispositivos, reagentes, sistemas, equipos y métodos de diagnóstico relacionados para predecir respuestas individuales variadas, tales como, por ejemplo, eficacia o efecto adverso a los agentes terapéuticos, p. ej., inhibidores de ciertos transportadores de neurotransmisores, tales como liafensine.
ARP210100576A 2020-03-06 2021-03-05 Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores AR121515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062986603P 2020-03-06 2020-03-06

Publications (1)

Publication Number Publication Date
AR121515A1 true AR121515A1 (es) 2022-06-08

Family

ID=77613738

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100576A AR121515A1 (es) 2020-03-06 2021-03-05 Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores

Country Status (13)

Country Link
US (1) US20230193388A1 (es)
EP (1) EP4106872A4 (es)
JP (1) JP2023515665A (es)
KR (1) KR20230005816A (es)
CN (1) CN115515680A (es)
AR (1) AR121515A1 (es)
AU (1) AU2021231683A1 (es)
BR (1) BR112022017770A2 (es)
CA (1) CA3174572A1 (es)
IL (1) IL296168A (es)
MX (1) MX2022010816A (es)
TW (1) TW202146660A (es)
WO (1) WO2021178166A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114848835B (zh) * 2022-03-22 2023-08-25 暨南大学 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2021502A4 (en) * 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
WO2008065544A2 (en) * 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
EP2243834A1 (en) * 2007-03-05 2010-10-27 Cancer Care Ontario Assessment of risk for colorectal cancer
US20170029892A1 (en) * 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
US8355927B2 (en) * 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
EP2710147A1 (en) * 2011-05-18 2014-03-26 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
US20140274764A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20170253928A1 (en) * 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
PL3117012T3 (pl) * 2014-03-14 2019-08-30 Caredx, Inc. Sposoby monitorowania terapii immunosupresyjnych u biorcy przeszczepu

Also Published As

Publication number Publication date
CN115515680A (zh) 2022-12-23
KR20230005816A (ko) 2023-01-10
WO2021178166A1 (en) 2021-09-10
AU2021231683A1 (en) 2022-09-22
US20230193388A1 (en) 2023-06-22
TW202146660A (zh) 2021-12-16
CA3174572A1 (en) 2021-09-10
EP4106872A4 (en) 2024-04-10
MX2022010816A (es) 2022-12-13
IL296168A (en) 2022-11-01
BR112022017770A2 (pt) 2022-11-29
JP2023515665A (ja) 2023-04-13
EP4106872A1 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
ECSP19031545A (es) Composiciones de células t con car anti-bcma
CL2021001883A1 (es) Receptores antigénicos quiméricos gprc5d y células que los expresan.
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
CO2020002588A2 (es) Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer
CL2019003015A1 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
BR112022008522A2 (pt) Usos de receptores de antígeno quimérico anti-bcma
BR112018012914A2 (pt) composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
GT201000088A (es) 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CR20120303A (es) Tratamientos para trastornos gastrointestinales
CO2022013827A2 (es) Compuestos y métodos para modular el empalme
BR112016026950A2 (pt) composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas
BR112022022409A2 (pt) 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
CL2019001668A1 (es) Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil.
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
BR112019004123A2 (pt) sistemas e métodos para atuar dispositivos hidraulicamente atuados
CO2022015926A2 (es) Compuestos y métodos para modular el empalme
BR112013017499A2 (pt) combinação de sirosingopina e inibidores mitocondriais para o tratamento de câncer e imunossupressão
AR121515A1 (es) Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
CO2022015925A2 (es) Compuestos y métodos para modular el corte y empalme
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario